Neoadjuvant sacituzumab govitecan for muscle-invasive bladder cancer

(40)

Neoadjuvant sacituzumab govitecan showed promising activity in muscle-invasive urothelial bladde...

(4:34)

ESMO 2020 Highlights on sacituzumab govitecan in metastatic TNBC: The ASCENT study

(3:5)

Study of sacituzumab govitecan for triple-negative breast cancer

(5:16)

ASCENT-05: sacituzumab govitecan and pembrolizumab in TNBC

(1:8)

The ASCENT of sacituzumab govitecan in metastatic TNBC | Aditya Bardia

(3:31)

ASCENT: sacituzumab govitecan biomarker analysis

(2:15)

ASCENT: Sacituzumab govitecan vs treatment of physician’s choice in patients with previously tre...

(7:14)

ASCENT-04: sacituzumab govitecan and pembrolizumab in PD-L1-positive TNBC

(1:58)

Efficacy of sacituzumab govitecan by Trop-2 expression in patients with mUC

(2:16)

Treatment advances in TNBC

(2:5)

Dr Cigliola on the Efficacy of Sacituzumab Govitecan in MIBC

(59)

ASCENT trial: sacituzumab govitecan for TNBC

(3:10)

TROPiCS-02: sacituzumab govitecan in HR+/HER- breast cancer

(1:)

Sacituzumab govitecan effective for HR+ metastatic breast cancer regardless of Trop-2 status

(1:34)

Promising novel approaches to the treatment of TNBC

(1:58)

TROPHY-U-01: Sacituzumab Govitecan for Platinum-ineligible Metastatic UC

(2:7)

TROPHY-U-01 Cohort 3: sacituzumab govitecan + pembrolizumab for patients with mUC

(2:38)

Neelima Denduluri, MD -- Treatment of Triple Negative Breast Cancer

(33:30)

ASCENT: sacituzumab govitecan shows promise in mTNBC patients

(4:25)